STAT+: Obesity drugmakers are testing in kids as young as 6

Vera seeks kidney drug approval, early data from Syntis Bio, and other biotech news from The Readout Adobe Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I was devastated to find out that we’ll no longer get sunsets after 7 p.m. until next spring. The need-to-know this morning Legend Biotech appointed Ingrid Zhang as its new CEO. Zhang is a former Novartis executive. She replaces Ying Huang, who resigned in July. With strong data, Vera to seek full approval of kidney drug Vera said this morning that its recently launched drug stabilized kidney function and reduced the risk of kidney-related death and other complications in a two-year trial of people with a chronic autoimmune kidney disease. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.